Patient group
Erwachsene mit unzureichend kontrolliertem hypereosinophilem Syndrom ohne erkennbare, nicht-hämatologische sekundäre Ursache
Hint of considerable added benefit
Comparator
Therapie nach ärztlicher Maßgabe
final resolution2022-05-19active
Arzneimittel-Richtlinie/Anlage XII: Mepolizumab (Neues Anwendungsgebiet: Hypereosinophiles Syndrom)
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Structured conclusion
Final result by patient group
1 source-verified result
Decision orientation
What the G-BA did
4 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2022-05-19
- Effective
- 19.05.2022
- Action type
- final resolution
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V
A listed target is not treated as a new directive version unless an official version source exists.
Official document package